Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.43 |
| ▸ | XDH | P47989 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15968271 | 0.85 | CNR1 (0.43) | CNR1FFAR4CNR2LRRK2 | |
| SCHEMBL15351916 | 0.82 | DPP4 (0.50) | CNR1XDHMAP4K4CNR2 | |
| SCHEMBL440247 | 0.82 | XDH (0.41) | CNR1XDHMAP4K4NR1H4RXRA | |
| SCHEMBL15350740 | 0.82 | XDH (0.41) | CNR1XDHMAP4K4NR1H4RXRA | |
| SCHEMBL14761488 | 0.81 | CA2 (0.45) | XDHMAP4K4CNR2 | |
| SCHEMBL411079 | 0.81 | CNR1 (0.53) | CNR1FFAR4CNR2 | |
| SCHEMBL2704405 | 0.80 | CNR1 (0.66) | CNR1FFAR4XDHMAP4K4KDM4C | |
| SCHEMBL15968953 | 0.78 | FFAR4 (0.48) | FFAR4KDM4CNR1H4 | |
| SCHEMBL3369108 | 0.78 | MAPT (0.50) | RXRA | |
| SCHEMBL15633550 | 0.78 | LRRK2 (0.39) | CNR1FFAR4LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2772485-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | CNR1 445/4885FFAR4 3702/4885XDH 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.